REFRACTORY AL AMYLOIDOSIS
Clinical trials for REFRACTORY AL AMYLOIDOSIS explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY AL AMYLOIDOSIS trials appear
Sign up with your email to follow new studies for REFRACTORY AL AMYLOIDOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Tough-to-Treat amyloidosis: 3-Drug combo enters human testing
Disease control OngoingThis early-phase study tests a combination of three drugs (venetoclax, ixazomib, and dexamethasone) in 24 people with a rare blood disease called light chain amyloidosis that has returned or not responded to prior therapy. The goal is to find the best dose and check for side effe…
Matched conditions: REFRACTORY AL AMYLOIDOSIS
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 07:21 UTC
-
New hope for hard-to-treat amyloidosis patients with prior daratumumab exposure
Disease control OngoingThis study tests a combination of three drugs (daratumumab, pomalidomide, and dexamethasone) in 15 adults with AL amyloidosis whose disease has returned or not responded after prior treatment including daratumumab. The goal is to see if this triple therapy leads to more complete …
Matched conditions: REFRACTORY AL AMYLOIDOSIS
Phase: PHASE2 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated May 13, 2026 16:03 UTC